Skip to main content
. 2021 Apr 26;14(7):101080. doi: 10.1016/j.tranon.2021.101080

Fig. 1.

Fig. 1

Expression and survival analysis of DLL3. (A–C) IHC staining of DLL3 in IBC samples (200 × magnification) including (A) Negative control of IHC performed on the IBC tissue using nonimmune IgG instead of the primary antibody; (B) Low DLL3 expression in the tumor tissue; (C) High DLL3 expression in the tumor tissue. In our cohort: (D) DLL3 expression in normal and tumor tissues; (E) Paired analysis; (F) Kaplan–Meier survival analysis of IBC patients with OS based on DLL3 expression. In TCGA–BRCA cohort: (G) DLL3 expression in normal and tumor tissues; (H) Paired analysis; (I) Kaplan–Meier survival analysis.